Pulsenmore Ltd. (PLSM)
| Market Cap | 26.54M -44.1% |
| Revenue (ttm) | 12.55M +314.3% |
| Net Income | -4.97M |
| EPS | -0.77 |
| Shares Out | 6.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,072 |
| Open | 3.280 |
| Previous Close | 3.260 |
| Day's Range | 3.100 - 3.390 |
| 52-Week Range | 3.000 - 12.970 |
| Beta | 0.44 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 14, 2026 |
About PLSM
Pulsenmore Ltd., a medical device company, engages in the research, development, manufacture, marketing, and sale of portable ultrasound solutions. The company provides Pulsenmore ES and Pulsenmore FC products. The company was incorporated in 2014 and is based in Omer, Israel.
Financial Performance
In 2025, Pulsenmore's revenue was 40.02 million, an increase of 314.28% compared to the previous year's 9.66 million. Losses were -15.85 million, -56.85% less than in 2024.
Financial numbers in ILS Financial StatementsNews
Pulsenmore to participate in Israel’s Healthcare AI Regulatory Sandbox Program
Pulsenmore (PLSM)announced that it has been selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health. Pul...
Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project
The program is designed to enable Pulsenmore to develop and clinically validate AI applications that improve clinical workflow efficiency and enhance the scalability of the company's home ultrasound p...
Pulsenmore registers to sell 3.125M ordinary shares for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.125M ordinary shares. The company is not selling any shares under…
Pulsenmore announces $7.5M private placement
Pulsenmore (PLSM)announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 ordinary shares and ordinar...
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor
RAMAT GAN, Israel, June 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it has entered into a securities purchase ag...
Why Is Penny Stock Pulsenmore (PLSM) Up Today?
Pulsenmore stock rallied on Wednesday alongside a new strategic collaboration.
Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States
FDA-authorized home ultrasound technology to be integrated into Ouma Health's virtual maternity care model, creating a scalable pathway to expand the adoption of home ultrasound in prenatal care acros...
Pulsenmore Announces Full Year 2025 Financial Results and Webcast
Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update OMER, Israel, March 30, 2026 /PRNewswire/ – Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM...
Pulsenmore Announces Full Year 2025 Earnings Conference Call
OMER, Israel, March 25, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that it will release its financial results for full y...
Pulsenmore Ltd. Ordinary Shares trading resumes
09:39 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading resumes
Pulsenmore Ltd. Ordinary Shares trading halted, volatility trading pause
09:34 EST Pulsenmore (PLSM)Ltd. Ordinary Shares trading halted, volatility trading pause
Pulsenmore announces commercial engagement with TLC Perinatal PA
Pulsenmore (PLSM)announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women’s ultrasound practice in Maryland, as part of its growing U.S. rollout. In early Febru...
Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
OMER, Israel, Feb. 9, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a ma...
Pulsenmore announces first commercial engagement with medical center in the U.S.
Pulsenmore (PLSM)announced a first commercial engagement with a medical center in the U.S., following receipt of FDA approval for its home pregnancy ultrasound product. At the end of January 2026,
Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
OMER, Israel, Feb. 2, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in ...
Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation
Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month pilot; Service to be deployed via Beilinson NEXT, Beilinson's virtual hospital RAMAT GAN, Israe...
Pulsenmore to commence trading on Nasdaq
Pulsenmore (PLSM)announced that its shares will begin trading on Nasdaq at the U.S. market open on January 21. The company’s shares will trade under the ticker symbol “PLSM” on the
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S.
RAMAT GAN, Israel, Jan. 21, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced that its shares will begin trading on Nasdaq at ...